Expertise in
6
conditions

Dr. Lloyd T. Miyawaki

Radiation Oncology
Yosemite Pathology Medical Group Inc
4301 N Star Way, 
Modesto, CA 
Offers Telehealth
Expertise in
6
conditions
Yosemite Pathology Medical Group Inc
4301 N Star Way, 
Modesto, CA 

Overview

Lloyd Miyawaki is a Radiation Oncologist practicing medicine in Modesto, California.

Dr. Miyawaki is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Pleuropulmonary Blastoma, and Breast Cancer.

He is actively involved in clinical research, participating in 10 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in CA

Hospital Affiliations

Marinhealth Medical Center
Novato Community Hospital
Ucsf Medical Center
Sonoma Valley Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 7 Less Insurance Carriers -

Locations

Yosemite Pathology Medical Group Inc
4301 N Star Way, Modesto, CA 95356

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone
Study Phase: Phase 3
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: May 22, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer
Enrollment Status: Terminated
Publish Date: May 22, 2026
Intervention Type: Radiation
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: May 08, 2026
Intervention Type: Radiation, Drug
Study Phase: Phase 3
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 23, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Capecitabine, Chemotherapy, Erlotinib hydrochloride, Fluorouracil, Gemcitabine hydrochloride
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 3
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Radiation, Drug
Study Drugs: Enzalutamide, Bicalutamide, GnRH analog
Study Phase: Phase 2
View 9 Less Clinical Trials
Similar Doctors
Expertise in
12
conditions
Dr. Megan E. Daly
Radiation Oncology
Expertise in
12
conditions
Dr. Megan E. Daly
Radiation Oncology
Referral may be required
Before you request

Megan E. Daly, MD Private Practice

3850 G St, 
Merced, CA 
 (38.5 miles away)
209-564-3601
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Megan E. Daly is a board-certified UCI Health radiation oncologist.She earned her medical degree and completed a residency in radiation oncology at Stanford University School of Medicine. Dr. Daly is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Gastrostomy, and Microvascular Decompression. Dr. Daly is board certified in American Board Of Radiology - Radiation Oncology and Radiology Radiation Oncology. Dr. Daly is currently accepting new patients.

Expertise in
64
conditions
Dr. Lynn S. Million
Radiation Oncology
Expertise in
64
conditions
Dr. Lynn S. Million
Radiation Oncology
Referral may be required

Interventional Radiology In San Jose

2589 Samaritan Dr, 
San Jose, CA 
 (60.5 miles away)
408-426-4900
Languages Spoken:
English
See accepted insurances

Lynn Million is a Radiation Oncologist practicing medicine in San Jose, California. Dr. Million is highly rated in 64 conditions, according to our data. Her clinical expertise encompasses Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Synovial Sarcoma, and Mycosis Fungoides.

Expertise in
18
conditions
Dr. Joseph C. Poen
Radiation Oncology
Expertise in
18
conditions
Dr. Joseph C. Poen
Radiation Oncology
Referral may be required

Yosemite Pathology Medical Group Inc

4301 N Star Way, 
Modesto, CA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Poen is a Radiation Oncologist practicing medicine in Modesto, California. Dr. Poen is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Polymorphous Low Grade Adenocarcinoma, Pleuropulmonary Blastoma, Cholangiocarcinoma (Bile Duct Cancer), and Gastroesophageal Junction Cancer.

Frequently Asked Questions about Dr. Lloyd T. Miyawaki

Is Dr. Lloyd T. Miyawaki a top-rated expert for Prostate Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lloyd T. Miyawaki is classified as an Distinguished expert for Prostate Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lloyd T. Miyawaki specialize in?

While Dr. Lloyd T. Miyawaki is a Radiation Oncology, they have specific expertise in Prostate Cancer, Familial Prostate Cancer, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Lloyd T. Miyawaki accept my insurance?

Dr. Lloyd T. Miyawaki accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Miyawaki's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile